WS #16404
Moderna ($MRNA) shares plummeted approximately 18% after early leaks of disappointing data from its melanoma cancer vaccine trial with Merck. Despite hitting some targets, the results were insufficient to meet investor expectations, erasing roughly $12 billion in market capitalization. This event highlights the continued high risk and volatility in the biotech sector, particularly for companies relying on single-candidate pipelines.
Biotech Selloff
Moderna ($MRNA) shares plummeted approximately 18% after early leaks of disappointing data from its melanoma cancer vaccine trial with Merck. Despite hitting some targets, the results were insufficient to meet investor expectations, erasing roughly $12 billion in market capitalization. This event highlights the continued high risk and volatility in the biotech sector, particularly for companies relying on single-candidate pipelines.